Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

Science translational medicine - 18 Feb 2026

Chen Li-Hsien, Lin Peng-Chan, Yeh Yu-Min, Li Chung-I, Chang Lian-Yun, Chang Jang-Yang, Shen Meng-Ru

Abstract excerpt

Chemotherapy-induced peripheral neuropathy (CIPN) remains a major unmet challenge in oncology, affecting treatment adherence and patient quality of life. Despite its prevalence, reliable predictive biomarkers and targeted neuroprotective strategies remain elusive. This study integrates clinical data, whole-genome sequencing, and translational research to identify genetic determinants of CIPN susceptibility and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain-Derived Neurotrophic Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Mice, Transgenic

Share to Oxaliplatin

Share to Peripheral Nervous System Diseases

Share to Quality of Life

Source

Identifiers

PMID: 41706872
DOI: 10.1126/scitranslmed.adx1436

Genes

BDNF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.PMID 41706872Read ↗

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.Semantic proximity Read ↗

Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.Semantic proximity Read ↗

Identification of Rare Variants in Candidate Genes Associated with Chemotherapy-Induced Peripheral NeuropathySemantic proximity Read ↗

Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.Semantic proximity Read ↗

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.Semantic proximity Read ↗

Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side EffectSemantic proximity Read ↗

Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)Semantic proximity Read ↗

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.Semantic proximity Read ↗

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.Semantic proximity Read ↗

Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.Semantic proximity Read ↗

Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.Semantic proximity Read ↗

The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.